Outcomes by Treatment Duration Summary

In transplant-ineligible patients with newly diagnosed multiple myeloma

Stay the course with your starting choice

Treat with DARZALEX^® + Rd until progression or unacceptable toxicity¹

In the primary analysis of patients undergoing treatment to progression or unacceptable toxicity, continuous DRd vs Rd led to^1,2:

Deeper clinical responses

Improved overall survival

Established safety profile

Treating to progression in the frontline setting may offer the opportunity for improved outcomes³

For the chance to achieve outcomes seen in the MAIA trial, set treatment expectations for continuous DARZALEX^® + Rd up front¹

Seek Durability

Treat to Progression

Improve Outcomes

DRd=DARZALEX^® + lenalidomide (R) + dexamethasone (d); Rd=lenalidomide (R) + dexamethasone (d).

References:

DARZALEX^® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
Facon T, Kumar S, Plesner T, et al; the MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115. doi:10.1056/NEJMoa1817249
Moreau P, Facon T, Usmani SZ, et al. Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study. Poster presented at: 19th International Myeloma Society (IMS) Annual Meeting; August 25-27, 2022; Los Angeles, CA.